Willingness of women with early estrogen receptor-positive breast cancer to take adjuvant CDK4/6 inhibitors.
Conclusions: The willingness of patients with estrogen receptor-positive bca to take an adjuvant cdk4/6 inhibitor will greatly depend on the expected benefit and toxicities described to them as well as on worry about bca recurrence.
PMID: 32669921 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Oral Cancer | Toxicology | Women